Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1614 1636 1658 1678 3791
This examiner grants 59% of resolved cases
Catherine S. Hibbert is an examiner in Art Unit 1614, part of Tech Center 3700. She has managed 810 resolved cases, providing a robust data set for analysis. Her allowance rate is 58.9 percent, which is a solid indicator of a fair examination process. This 58.9 percent rate suggests that more than half of the applications she reviews result in a granted patent, provided the claims are well-supported. The 810 resolved cases establish a reliable baseline for predicting outcomes in Art Unit 1614.
The interview lift for this examiner is 48.8 percent. This is an exceptionally high lift, suggesting that interviews are one of the most effective tools available to practitioners. The 48.8 percent increase over the baseline allowance rate of 58.9 percent implies that verbal advocacy is highly persuasive or helpful in her decision-making process. Applicants should prioritize interviews as a central part of their strategy to maximize their chances of success in Tech Center 3700.
The median days to allowance for her cases is 1403. This timeline is a bit longer than average, indicating that prosecution in Art Unit 1614 can be a deliberate process. Applicants should be prepared for a pendency of 1403 days. Despite the 1403-day median, the 58.9 percent allowance rate and the 48.8 percent interview lift provide a clear path forward for those willing to invest the necessary time and effort. The 1403-day duration is a critical factor for long-term planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18402684 | DRUG DELIVERY COMPOSITIONS AND METHODS OF CONTROLLING DRUG DELIVERY RATES OF SUBCUTANEOUS SENSORS | Non-Final OA | ABBOTT DIABETES CARE INC. |
| 18686840 | IMMUNE CHECKPOINT TARGETING THERAPEUTIC NANOPARTICLES | Non-Final OA | The Regents of the University of California |
| 18050423 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18185449 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | Non-Final OA | The University of Hong Kong |
| 18728814 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Non-Final OA | Mannkind Corporation |
| 18605198 | VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS | Non-Final OA | The United States of America, as represented by the Secretary, Department of Health and Human Serv. |
| 18835427 | COMPOSITIONS AND METHODS RELATING TO ATP/P2X7R SIGNALING INHIBITION | Non-Final OA | THE CHILDREN'S MEDICAL CENTER CORPORATION |
| 18006854 | BIOSTIMULANT AND BIOPROTECTIVE PEPTIDES AND THEIR USE IN AGRICULTURE | Non-Final OA | MATERIAS S.R.L. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy